About EvolveImmune Therapeutics
EvolveImmune Therapeutics is a private company based in Branford, Connecticut, incorporated in 2019 in Delaware. It has reported $85,776,146 raised in four offerings on Form D since January 2020. Its chief executive is Stephen Bloch.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 22, 2024 | Nov 1, 2024 | $20,000,003fully sold | 1 | $20.0M | EquityRule 506(b) | Form D ↗ |
| Nov 15, 2023 | Nov 16, 2023 | $37,398,371of $57.3M target | 9 | $4.1M | EquityRule 506(b) | Form D ↗ |
| Jan 18, 2023 | Jan 19, 2023 | $10,827,780of $26.0M target | 8 | $1.3M | Debt, Options, Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Jan 8, 2020 | Jan 17, 2020 | $17,549,992of $35.0M target | 8 | $2.1M | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $85,776,146 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on EvolveImmune Therapeutics's Form D filed Nov 1, 2024.

Donmienne Leung
Director
First appears on the Form D that EvolveImmune Therapeutics filed on November 1, 2024; on 1 of its 4 filings.
Donmienne Leung appears on 2 Form D filings at 2 companies:
- EvolveImmune Therapeutics, director: Nov 1, 2024
- EndLyz, director, AbbVie ventures: May 7, 2026
IT
Ian Taylor
Director
First appears on the Form D that EvolveImmune Therapeutics filed on January 19, 2023; on 3 of its 4 filings.
DY
Derek Yoon
Director
First appears on the Form D that EvolveImmune Therapeutics filed on January 19, 2023; on 3 of its 4 filings.

Stephen Bloch
Co-founder and Chief Executive Officer, director
On every Form D that EvolveImmune Therapeutics has filed: 4 filings, from Jan 17, 2020 to Nov 1, 2024.
Stephen Bloch appears on 23 Form D filings at 8 companies. Show all
- Marinus Pharmaceuticals, chairman of the board of directors: Apr 22, 2009
- Liquidia Technologies, chairman: Jul 15, 2009 · Jan 21, 2010 (amended) · May 25, 2010 (amended) · Mar 3, 2011 · Jul 2, 2012 (amended) · Feb 20, 2018 · Jan 7, 2020
- Envisia Therapeutics, director: Nov 22, 2013
- LQ3 Pharmaceuticals, director: Jul 23, 2014 · Dec 17, 2014 (amended)
- Envisia Therapeutics, director: Oct 19, 2015 · Mar 17, 2016
- EvolveImmune Therapeutics, co-founder and chief executive officer, director: Jan 17, 2020 · Jan 19, 2023 · Nov 16, 2023 · Nov 1, 2024
- Liquidia, director: Apr 16, 2021
- Allyx Therapeutics, CEO & co-founder, director: Jun 2, 2021 · Feb 10, 2023 · Mar 3, 2026 · May 11, 2026 · Oct 21, 2026 (amended)
JM
Jasmina Marjanovic
Director
First appears on the Form D that EvolveImmune Therapeutics filed on November 1, 2024; on 1 of its 4 filings.
DP
Denis Patrick
Director
On every Form D that EvolveImmune Therapeutics has filed: 4 filings, from Jan 17, 2020 to Nov 1, 2024.
Earlier filings also listed
- Alessandra Di Bacco · directorLast listed on the Form D that EvolveImmune Therapeutics filed on November 16, 2023; on 3 of its 4 filings.
- Hugo Beekman · directorLast listed on the Form D that EvolveImmune Therapeutics filed on January 17, 2020; on 1 of its 4 filings.
